DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION

美国艾滋病防治研究所致力于开展必要的研究，以终止艾滋病毒/艾滋病的流行，并寻找新的、更有效的免疫疗法，补充抗逆转录病毒药物组合。艾滋病毒预防疫苗旨在解决未感染者接触艾滋病毒的后果，即在发生感染时获得病毒或减少病毒载量。到目前为止，这类疫苗在被感染者身上尚未显示出治疗效果。因此，需要对感染者有效的创新治疗性生物产品。最近的研究还发现了许多抗艾滋病毒中和抗体，这些抗体的特性表明它们可能是有用的治疗剂。这些抗体具有有用和新颖的特性，包括效力、广泛的中和范围和其他抗体介导的效应功能。进一步的研究表明，某些抗体可能被改造以提高结合特异性、效力或抗体效应功能。人们对根除艾滋病毒或持续缓解的可能性也越来越感兴趣，因为治疗性骨髓移植可以明显治愈艾滋病毒，对新生儿进行立即和积极的抗逆转录病毒治疗可以明显治愈艾滋病毒。人们还对治疗性抗艾滋病毒疫苗、抗艾滋病毒抗体产品或其他基于免疫的抗艾滋病毒产品特别感兴趣，这些产品将作为治疗成套设备的一部分，作为艾滋病毒持续抑制/根除人体临床试验的一部分进行测试，以确定安全性和有效性。

NIAID is committed to research necessary to end the HIV/AIDS epidemic and in finding new and more effective immune based therapies that complement antiretroviral drug combinations (cART). HIV prevention vaccines are designed to address outcomes of exposure in uninfected persons, i.e. acquisition of virus or attenuation of viral load when infection occurs. Thus far, such vaccines have not demonstrated therapeutic efficacy when used in infected subjects. Thus the need exists for innovative therapeutic biological products that work in infected persons. Recent research has also identified numerous anti-HIV neutralizing antibodies with properties that suggest they may be useful as therapeutic agents. These antibodies have useful and novel properties including potency, broad ranges of neutralization, and other antibody-mediated effector functions. Additional research indicates certain antibodies may be engineered to improve binding specificity, potency, or antibody effector function. There is also heightened interest in the possibility of HIV eradication or sustained remission based on one apparent HIV cure due to therapeutic bone marrow transplant, and one apparent cure due to immediate and aggressive antiretroviral therapy in a newborn. There is also a specific interest in therapeutic anti-HIV vaccine, anti-HIV antibody products, or other immune-based anti-HIV products being part of a cure armamentarium to be tested as part of HIV sustained suppression/eradication human clinical trials to determine safety and efficacy.